Phaseline

Companies › Turn Therapeutics

Turn Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Immunology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GX-03–Phase 2Eczema Atopic DermatitisJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07355075GX-03Phase 2Eczema Atopic DermatitisImmunologyJan 2027

From the company's SEC filings

Cash of $9m on 2026-09-30; operating cash outflow about $6m a year; runway about 20 months at that burn, to Jun 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cellcolabs Clinical SPV EHL Bio Nature Cell Throne Biotechnologies Xentria

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.